Publications by authors named "V Maisnar"

Claim this Profile
P
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.
Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Anna Lysén, Norma C Gutiérrez, Vladimir Maisnar

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Alexandra Jungova, Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Vladimir Maisnar

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?
M Talarico, S Barbato, V Maisnar, S Delimpasi, M Puppi

J Cancer Res Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.
Martin Stork, Jakub Radocha, Jana Mihalyova, Ivan Spicka, Tomas Pika, Vladimir Maisnar

Ann Hematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.
Jiri Minarik, Ludek Pour, Vojtech Latal, Tomas Jelinek, Jan Straub, Vladimir Maisnar

BMC Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis